Clicky

Tetralogic Pharmaceu(TLOG)

Description: TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.


Keywords: Biopharmaceutical Life Sciences Infectious Diseases Organ Systems Autoimmune Disease Lymphoma Orphan Drug Drug Design Small Molecule Therapies Apoptosis Alopecia Ctc Tcl Alopecia Areata Cutaneous T Cell Lymphoma

Home Page: www.tetralogicpharma.com

343 Phoenixville Pike
Malvern, PA 19355
United States
Phone: 610 889 9900


Officers

Name Title
Dr. Yigong Shi Ph.D. Co-Founder
Sarah E. Frew Director of Bus. & Commercial Devel.

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4016
Price-to-Sales TTM: 0
IPO Date: 2013-12-12
Fiscal Year End: December
Full Time Employees: 29
Back to stocks